Journal of Pathology and Translational Medicine (대한병리학회지)

The Korean Society of Pathologists (대한병리학회)
권호 표지
DOI QR코드

DOI QR Code

The Usefulness of Immunocytochemistry of CD56 in Determining Malignancy from Indeterminate Thyroid Fine-Needle Aspiration Cytology

  • Cha, Hyunseo (Department of Pathology, Gangnam Severance Hospital) ;
  • Pyo, Ju Yeon (Department of Pathology, Gangnam Severance Hospital) ;
  • Hong, Soon Won (Department of Pathology, Gangnam Severance Hospital)
  • Received : 2018.07.06
  • Accepted : 2018.09.18
  • Published : 2018.11.15
⟨ Previous Next ⟩

Abstract

Background: Fine-needle aspiration cytology serves as a safe, economical tool in evaluating thyroid nodules. However, about 30% of the samples are categorized as indeterminate. Hence, many immunocytochemistry markers have been studied, but there has not been a single outstanding marker. We studied the efficacy of CD56 with human bone marrow endothelial cell marker-1 (HBME-1) in diagnosis in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) category III. Methods: We reviewed ThinPrep liquid-based cytology (LBC) samples with Papanicolaou stain from July 1 to December 31, 2016 (2,195 cases) and selected TBSRTC category III cases (n=363). Twenty-six cases were histologically confirmed as benign (six cases, 23%) or malignant (20 cases, 77%); we stained 26 LBC slides with HBME-1 and CD56 through the cell transfer method. For evaluation of reactivity of immunocytochemistry, we chose atypical follicular cell clusters. Results: CD56 was not reactive in 18 of 20 cases (90%) of malignant nodules and showed cytoplasmic positivity in five of six cases (83%) of benign nodules. CD56 showed high sensitivity (90.0%) and relatively low specificity (83.3%) in detecting malignancy (p=.004). HBME-1 was reactive in 17 of 20 cases (85%) of malignant nodules and was not reactive in five of six cases (83%) of benign nodules. HBME-1 showed slightly lower sensitivity (85.0%) than CD56. The specificity in detecting malignancy by HBME-1 was similar to that of CD56 (83.3%, p=.008). CD56 and HBME-1 tests combined showed lower sensitivity (75.0% vs 90%) and higher specificity (93.8% vs 83.3%) in detecting malignancy compared to using CD56 alone. Conclusions: Using CD56 alone showed relatively low specificity despite high sensitivity for detecting malignancy. Combining CD56 with HBME-1 could increase the specificity. Thus, we suggest that CD56 could be a useful preoperative marker for differential diagnosis of TBSRTC category III samples.

Keywords

References

  1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214. https://doi.org/10.1089/thy.2009.0110
  2. Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid 2016; 26: 1535-40. https://doi.org/10.1089/thy.2016.0075
  3. Cha YJ, Pyo JY, Hong S, et al. Thyroid fine-needle aspiration cytology practice in Korea. J Pathol Transl Med 2017; 51: 521-7. https://doi.org/10.4132/jptm.2017.09.26
  4. Powsner SM, Costa J, Homer RJ. Clinicians are from Mars and pathologists are from Venus. Arch Pathol Lab Med 2000; 124: 1040-6.
  5. Cibas ES, Ali SZ; NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 2009; 132: 658-65. https://doi.org/10.1309/AJCPPHLWMI3JV4LA
  6. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017; 27: 1341-6. https://doi.org/10.1089/thy.2017.0500
  7. Jung CK, Hong S, Bychkov A, Kakudo K. The use of fine-needle aspiration (FNA) cytology in patients with thyroid nodules in Asia: a brief overview of studies from the Working Group of Asian Thyroid FNA Cytology. J Pathol Transl Med 2017; 51: 571-8. https://doi.org/10.4132/jptm.2017.10.19
  8. Kang Y, Lee YJ, Jung J, Lee Y, Won NH, Chae YS. Morphometric analysis of thyroid follicular cells with atypia of undetermined significance. J Pathol Transl Med 2016; 50: 287-93. https://doi.org/10.4132/jptm.2016.04.04
  9. Yoo C, Choi HJ, Im S, et al. Fine needle aspiration cytology of thyroid follicular neoplasm: cytohistologic correlation and accuracy. Korean J Pathol 2013; 47: 61-6. https://doi.org/10.4132/KoreanJPathol.2013.47.1.61
  10. Oosthuizen JL, Walker B, Todorovic E, Masoudi H, Wiseman SM. The presence of papillary features in thyroid nodules diagnosed as atypia of undetermined significance or follicular lesion of undetermined significance increases cancer risk and should influence treatment. Am J Surg 2018; 215: 819-23. https://doi.org/10.1016/j.amjsurg.2017.12.018
  11. Yashaswini R, Suresh TN, Sagayaraj A. Cytological evaluation of thyroid lesions by nuclear morphology and nuclear morphometry. J Cytol 2017; 34: 197-202. https://doi.org/10.4103/JOC.JOC_87_16
  12. Vivero M, Renshaw AA, Krane JF. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. Cancer Cytopathol 2017; 125: 534-43. https://doi.org/10.1002/cncy.21858
  13. Rossi M, Lupo S, Rossi R, et al. Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses. Endocrine 2017; 57: 98-107. https://doi.org/10.1007/s12020-016-1105-4
  14. Satoh S, Yamashita H, Kakudo K. Thyroid cytology: The Japanese system and experience at Yamashita Thyroid Hospital. J Pathol Transl Med 2017; 51: 548-54. https://doi.org/10.4132/jptm.2017.09.29
  15. Kim SJ, Roh J, Baek JH, et al. Risk of malignancy according to subclassification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology. Cytopathology 2017; 28: 65-73. https://doi.org/10.1111/cyt.12352
  16. Misiakos EP, Margari N, Meristoudis C, et al. Cytopathologic diagnosis of fine needle aspiration biopsies of thyroid nodules. World J Clin Cases 2016; 4: 38-48. https://doi.org/10.12998/wjcc.v4.i2.38
  17. Kholova I, Ludvikova M. Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage? Acta Cytol 2014; 58: 319-29. https://doi.org/10.1159/000366498
  18. Shi Y, Ding X, Klein M, et al. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer 2009; 117: 298-304.
  19. Garg S, Naik LP, Kothari KS, Fernandes GC, Agnihotri MA, Gokhale JC. Evaluation of thyroid nodules classified as Bethesda category III on FNAC. J Cytol 2017; 34: 5-9. https://doi.org/10.4103/0970-9371.197590
  20. Rossi ED, Martini M, Capodimonti S, et al. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol 2013; 168: 853-9. https://doi.org/10.1530/EJE-13-0023
  21. Fadda G, Rossi ED, Raffaelli M, et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol 2011; 165: 447-53. https://doi.org/10.1530/EJE-11-0181
  22. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol 2010; 118: 17-23. https://doi.org/10.1002/cncy.20063
  23. Cochand-Priollet B, Dahan H, Laloi-Michelin M, et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fineneedle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid 2011; 21: 1067-73. https://doi.org/10.1089/thy.2011.0014
  24. Abouhashem NS, Talaat SM. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathol Res Pract 2017; 213: 509-17. https://doi.org/10.1016/j.prp.2017.01.017
  25. Solmaz OA. Diagnostic importance of CD56 with fine-needle aspiration cytology in suspected papillary thyroid carcinoma cases. Cytojournal 2018; 15: 3. https://doi.org/10.4103/cytojournal.cytojournal_42_17
  26. Mokhtari M, Eftekhari M, Tahririan R. Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology. J Res Med Sci 2013; 18: 1046-50.
  27. Nechifor-Boila A, Borda A, Sassolas G, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: the promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract 2013; 209: 585-92. https://doi.org/10.1016/j.prp.2013.06.012
  28. Nechifor-Boila˘ A, Ca˘tana˘ R, Loghin A, Radu TG, Borda A. Diagnostic value of HBME-1, CD56, galectin-3 and cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol 2014; 55: 49-56.
  29. Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 2007; 212: 411-9. https://doi.org/10.1002/path.2183
  30. Shahebrahimi K, Madani SH, Fazaeli AR, Khazaei S, Kanani M, Keshavarz A. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma. Indian J Pathol Microbiol 2013; 56: 2-5. https://doi.org/10.4103/0377-4929.116139
  31. Huang L, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett 2018; 15: 4269-77.
  32. Muzafar A, Bukhari MH, Qureshi IU. A study of galactin-3 on fine needle aspiration as a diagnostic marker differentiating benign from malignant thyroid neoplasm. Pak J Med Sci 2017; 33: 726-31.
  33. Golu I, Vlad MM, Dema A, et al. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions. Indian J Pathol Microbiol 2017; 60: 161-6. https://doi.org/10.4103/0377-4929.208378
  34. Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 2012; 24: 175-84. https://doi.org/10.1016/j.jnci.2012.10.002
  35. Ceyran AB, Senol S, Simsek BC, Sagiroglu J, Aydin A. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Int J Clin Exp Pathol 2015; 8: 3670-80.
  36. Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arslan A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci 2016; 21: 49. https://doi.org/10.4103/1735-1995.183986
  37. Oh EJ, Hong SW, Jeong HJ, Yoon SO. The diagnostic approach to fine-needle aspiration of malignant lymphoma: using cytomorphology and immunocytochemistry with cell transfer method. Diagn Cytopathol 2014; 42: 671-9. https://doi.org/10.1002/dc.23110
  38. Sherman ME, Jimenez-Joseph D, Gangi MD, Rojas-Corona RR. Immunostaining of small cytologic specimens: facilitation with cell transfer. Acta Cytol 1994; 38: 18-22.
  39. Zu Y, Gangi MD, Yang GC. Ultrafast Papanicolaou stain and celltransfer technique enhance cytologic diagnosis of Hodgkin lymphoma. Diagn Cytopathol 2002; 27: 308-11. https://doi.org/10.1002/dc.10180
  40. El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract 2009; 205: 303-9. https://doi.org/10.1016/j.prp.2008.11.011
  41. Zeromski J, Bagnasco M, Paolieri F, Dworacki G. Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol 1992; 89: 474-8.
  42. Ozolins A, Narbuts Z, Strumfa I, Volanska G, Stepanovs K, Gardovskis J. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas) 2012; 48: 507-14.